Moderna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.
Follow MRNA
Moderna, Inc. (MRNA) Shares outstanding
Moderna, Inc.'s shares outstanding at the end of fiscal 2025 was $389.0M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $398.0M. Over the past ten years it has ranged from $60.7M (fiscal 2016) to $431.0M (fiscal 2021); the current reading is higher than 80% of that period. Moderna, Inc. ranks 13th of 602 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $389.0M | 1.30% |
| FY2024 | $384.0M | 0.52% |
| FY2023 | $382.0M | (8.17%) |
| FY2022 | $416.0M | (3.48%) |
| FY2021 | $431.0M | 13.12% |
| FY2020 | $381.0M | 15.11% |
| FY2019 | $331.0M | 308.07% |
| FY2018 | $81.1M | 25.76% |
| FY2017 | $64.5M | 6.17% |
| FY2016 | $60.7M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $398.0M | 0.76% |
| Mar 2026 | $395.0M | 1.54% |
| Dec 2025 | $389.0M | (0.26%) |
| Sep 2025 | $390.0M | 0.52% |
| 30 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| RPRX Royalty Pharma PLC compare | $556.9M |
| MRNA Moderna, Inc. | $398.0M |
| VRTX Vertex Pharmaceuticals Incorporated compare | $255.2M |
| RVMD Revolution Medicines, Inc. compare | $210.9M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.3M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $115.8M |
| REGN Regeneron Pharmaceuticals, Inc. compare | $106.0M |
| ARGX argenex SE compare | $64.5M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement